TransCode Therapeutics Inc (RNAZ) 뉴스

Stargate landing on planet earth in texas with the cure to cancer🚀🚀🚀🚀

https://www.msn.com/en-us/money/companies/openai-says-data-center-in-texas-to-be-flagship-in-stargate-project/ar-AA1yy2i4

https://financialpost.com/pmn/business-pmn/openai-eyeing-more-data-centers-in-texas-other-states-for-stargate

MD Anderson and TransCode Therapeutics announce strategic alliance to advance RNA therapies for oncology

MD Anderson News Release August 02, 2022

The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.

Through the alliance, TransCode and MD Anderson scientists will collaborate on preclinical studies to further validate TransCode’s therapeutic and diagnostic candidates and to expand the reach of TransCode’s discovery engine. The results of these studies will inform future clinical trials with these agents, including trials to be led at MD Anderson.

“RNA-based therapeutics offer exciting possibilities to treat cancer. We can now examine how regulatory RNAs affect signaling, both spatially and temporally, at the single-cell level in tumor cells, immune cells and stem cells — all critical for tumor progression, relapse and immune evasion,” said principal investigator Sendurai Mani, Ph.D., professor of Translational Molecular Pathology at MD Anderson. “Our goals in collaborating with TransCode are to gain a deeper understanding of RNA-targeted therapies and to bring innovative new treatment options to our patients.”

The collaboration has the potential to inform multiple clinical programs in TransCode’s pipeline, starting with its lead therapeutic candidate, TTX-MC138, designed to treat multiple metastatic cancers. Future clinical trials will be designed and led by Vivek Subbiah, M.D., associate professor of Investigational Cancer Therapeutics at MD Anderson.

“This strategic alliance offers the opportunity to further unlock the potential of our therapeutic pipeline by combining the promise of our image capable delivery platform and discovery engine with the unique talent and resources found at MD Anderson,” said Zdravka Medarova, Ph.D., co-founder and chief technology officer of TransCode.

Prior to a Phase I clinical trial, TTX-MC138 is scheduled to enter a first-in-human Phase 0 clinical trial designed to demonstrate delivery of the therapeutic candidate to metastatic lesions in patients with advanced solid tumors.

“We are acutely aware of the expectations that come with a therapeutic approach that has the potential to induce durable regressions of metastatic disease. We are committed to taking every opportunity to fulfill the promise of RNA in cancer,” said Michael Dudley, co-founder and chief executive officer of TransCode.

E Pluribus Unum Brothers Cure To Cancer Moment $10,000

Is it monday yet..News could land on planet earth anytime now …
https://www.tipranks.com/news/ratings/promising-clinical-developments-drive-buy-rating-for-transcode-therapeutics

Billion dollar market cap will land on planet earth and will rattle the world with the cure to cancer🚀🚀🚀🚀🚀

The revolutionary TTX-CRISPR: A CRISPR/Cas9-based therapy platform for gene repair or elimination in tumor cells.

TTX- stargate material TTX-MC138: A clinical stage product for treating metastatic cancer.
- TTX-siPDL1: An siRNA-based modulator targeting programmed death-ligand 1.
- TTX-siLIN28B: An siRNA-based inhibitor targeting RNA-binding protein LIN28B.
- TTX-RIGA: An RNA-based agonist for the RIG-I-driven immune response in the tumor microenvironment.
- TTX-CRISPR: A CRISPR/Cas9-based therapy platform for gene repair or elimination in tumor cells.
- TTX-mRNA: An mRNA-based platform for developing cancer vaccines.

Nobel prize micro Rna breakthrough at the highest level of research
No safety concerns or dose limiting toxicities reported across all nine patients
TTX-MC138 achieved 66% inhibition of miR-10b at 24 hours post-infusion
Successful dose escalation with increased activity in Cohort 2
PK/PD profile consistent with preclinical and Phase 0 results
Multiple patients continuing treatment in 28-day cycles

Stay tuned for news next week for the billion dollar market cap news🚀🚀🚀

Criminal pedlar short motherfucker rat bastards are still in control till 100m market cap is obtained

New tripple bottom foundation of all the nations🚀🚀🚀🚀

Green coming🚀🚀🚀

Load now strong hands in play 🚀🚀🚀🚀

It’s healthy to take a shit on all the nigga shorts,

Hold up the fort brother, Ai cure to cancer bots want your shares, hold on to your dirty underwears🚀🚀🚀🚀🚀

Any idea why vol was so big last 2 days? Today no that much

Up and down like a yo-yo..

Ai Cure to cancer bots about to activate🚀🚀🚀

Get ready brothers🚀🚀🚀🚀

Consolidation of all the nations cancer cure earthquake going to hit planet earth

Gut it out brothers, squeeze time🚀🚀🚀🚀

Load up before the atomic bots take over the cure to cancer is here🚀🚀🚀🚀

Blink blink 100$

Let’s all hold hands and push to the next frontier of cancer research 🚀🚀🚀

A message to all the short criminal motherfucker rat bastards of the earth, who tried to sabotage the only hope for terminally ill cancer patients, eat shit motherfuckers

The cancer cure sabotage by big pharma rat bastard motherfuckers is over
https://nebraskajournalherald.substack.com/p/stargate-ais-cancer-cure-echoes-the

Let's go 

The world is watching now…
TTX-MC138: A clinical stage product for treating metastatic cancer.
- TTX-siPDL1: An siRNA-based modulator of programmed death-ligand 1.
- TTX-siLIN28B: An siRNA-based inhibitor of RNA-binding protein LIN28B.
- TTX-RIGA: An RNA-based agonist of the RIG-I-driven immune response in the tumor microenvironment.
- TTX-CRISPR: A CRISPR/Cas9-based therapy platform for repairing or eliminating cancer-causing genes inside tumor cells.
- TTX-mRNA: An mRNA-based platform for developing cancer vaccines to activate cytotoxic immune responses against tumor cells.

Goodmorning peeps, this is your captain speaking , fasten up your seatbelts and embrace yourselves for worldwide cancer cure impact

Cancer cure moment breakthrough🚀🚀 The holy grail in cancer treatment🚀🚀

You snooze you loose brothers🚀🚀🚀 take this to the bank 🚀🚀🚀
Analyses of PK data and pharmacodynamic (PD) activity from Cohorts 1 and 2 is ongoing. To date, the analyses suggest that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from TransCode's previous Phase 0 clinical trial. Specifically, results from Cohort 1 confirmed the Phase 0 observation that TTX-MC138 shows evidence of pharmacodynamic activity in the presence of high baseline expression of miR-10b, reaching a 66% inhibition at 24 hours after infusion, similar to that seen in the Phase 0 trial. Additionally, TTX-MC138 activity increased with the escalated dose administered in Cohort 2 and was consistent at subsequent administrations suggesting a favorable pharmacokinetic profile.

Make no mistakes TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Hold on to your dirty underwears brothers, The cure to cancer is here Oracle's Larry Ellison Says Cancer Vaccine Tailored In 48 Hours Could Soon Be A Reality As Trump Announces $500 Billion AI Investment

co-founder Larry Ellison unveiled plans for an artificial intelligence-driven cancer vaccine system that could deliver personalized treatments within 48 hours, speaking at a White House briefing alongside tech leaders and President Donald Trump on Tuesday.

What Happened: The announcement came as part of a broader $500 billion AI infrastructure initiative called Stargate, a joint venture between Oracle, OpenAI, and SoftBank Group. The project will establish massive data centers across the United States, starting with a facility in Abilene, Texas.

“We can diagnose cancer using AI through a simple blood test,” Ellison explained during the briefing. “Once we sequence the genes of that cancer tumor, we can design an mRNA vaccine for each individual robotically using AI in about 48 hours.”
https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment

Live the dream brothers
https://cloudwars.com/innovation-leadership/larry-ellison-and-stargate-ai-will-shatter-the-tyranny-of-impossible/

My texas cowboys🚀🚀Customised Cancer Treatment In 48 Hours? Trump’s $500B AI Plan Stargate Sparks Hopes
January 22, 2025, 13:02 IST
The project- named Stargate- was launched by OpenAI, SoftBank and Oracle in order to provide new technology with the help of large data centers based in Texas.

https://www.news18.com/amp/world/customised-cancer-treatment-in-48-hours-trumps-500b-ai-plan-stargate-sparks-hopes-and-debate-9197566.html

TTX-MC138 shows evidence of pharmacodynamic activity in the presence of high baseline expression of miR-10b, reaching a 66% inhibition at 24 hours after infusion, similar to that seen in the Phase 0 trial. Additionally, TTX-MC138 activity increased with the escalated dose administered in Cohort 2 and was consistent at subsequent administrations suggesting a favorable pharmacokinetic profile.

Ellison explained that Oracle was utilizing technology from Altman and Son’s companies to develop mRNA vaccines that are custom-tailored for every cancer patient that receives them. He claims this will eventually be made possible through AI examining a blood sample and developing a shot for the specific cancer within two days.
https://mugglehead.com/ai-behemoth-project-stargate-will-revolutionize-cancer-treatment-oracle-founder-ellison-says/?amp=1

Next leg up $weet$$$

Leg$ wide open and ready to $quirt to 20 buckarooo$$$. https://www.tipranks.com/news/ratings/promising-clinical-developments-drive-buy-rating-for-transcode-therapeutics

11.11 Now connected to the universe $weet$$ love you$$$

$how me the way $weet$$ Your mine$$$$

Drop your pant$ $lap my a$$ junkie$$$ I got your back$$$
https://jonrappoport.substack.com/p/rna-cancer-vaccines-created-by-ai-for-500-billion-dollars?utm_campaign=post&utm_medium=web

Fasten your seatbelts and embrace for impact, Blue skies up ahead dudes

Hold up the fort more news coming🚀🚀🚀🚀

Y’ all going to get a wake up call power hour🚀🚀🚀

It’s all in the pudding cure to cancer moment is here🚀🚀🚀Made in the USA

I see $1000 with great news, look at the float, somebody decide to take it it will fly like a rocket ship.. off course my opinion 

They can’t hold it down much longer🚀🚀🚀

100$ EOW Brother🚀🚀🚀🚀

They will only call when market cap is 8M with 696K outstanding 500k float trading 12M shares

Let's go back to $80,000 a share where we were 3 years ago.  This thing is about to blow!